Carfilzomib-Lenalidomide-Dexamethasone (krd) Vs. Lenalidomide-Dexamethasone (rd) in Newly Diagnosed Fit or Intermediate-Fit Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation (phase III EMN20 Trial): Analysis of Sustained Undetectable Minimal Residual Disease (MRD)
BLOOD（2023）
Key words
Minimal Residual Disease
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined